2M6 Stock Overview
Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Medtronic plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$81.76 |
| 52 Week High | US$86.00 |
| 52 Week Low | US$70.10 |
| Beta | 0.85 |
| 11 Month Change | -3.51% |
| 3 Month Change | 3.78% |
| 1 Year Change | 13.59% |
| 33 Year Change | -17.25% |
| 5 Year Change | -18.97% |
| Change since IPO | 11.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2M6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -2.5% | -1.3% |
| 1Y | 13.6% | -8.4% | 7.4% |
Return vs Industry: 2M6 exceeded the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: 2M6 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 2M6 volatility | |
|---|---|
| 2M6 Average Weekly Movement | 2.6% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2M6 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2M6's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 95,000 | Geoff Martha | www.medtronic.com |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
Medtronic plc Fundamentals Summary
| 2M6 fundamental statistics | |
|---|---|
| Market cap | €104.55b |
| Earnings (TTM) | €4.13b |
| Revenue (TTM) | €31.74b |
25.3x
P/E Ratio3.3x
P/S RatioIs 2M6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2M6 income statement (TTM) | |
|---|---|
| Revenue | US$33.00b |
| Cost of Revenue | US$11.41b |
| Gross Profit | US$21.58b |
| Other Expenses | US$17.29b |
| Earnings | US$4.29b |
Last Reported Earnings
Oct 25, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | 3.34 |
| Gross Margin | 65.41% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 58.1% |
How did 2M6 perform over the long term?
See historical performance and comparison